Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Female Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm
Female Reproductive System Neoplasm

Subtype

Female Reproductive System Neoplasm

CI-CAN-00000885Explore in graph →

Non-malignant1,629 active trials11 approved drugs139 evidence items

NCIt: C3053
MeSH: D005833

Overview
Statistics
Survival
Genomics36
Variants & evidence139
Drugs44
Trials7170
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (324)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 324 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
· Cancer · 2014 · PMID 24166148 · validated civic_curation pubmed
BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
· Gynecol Oncol · 2011 · PMID 21920589 · validated civic_curation pubmed
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
· Target Oncol · 2013 · PMID 23238879 · validated civic_curation pubmed
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
· Clin Cancer Res · 2014 · PMID 24240112 · validated civic_curation pubmed
Toward the molecular dissection of peritoneal pseudomyxoma.
· Ann Oncol · 2016 · PMID 27502722 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
· Gynecol Oncol · 2016 · PMID 26740259 · validated civic_curation

Showing 251–275 of 324 publications

← Previous
1
…
10
11
12
13
Next →

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

· Lancet Oncol · 2014 · PMID 25218906 · validated civic_curation pubmed

The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.

· PLoS One · 2015 · PMID 26422378 · validated civic_curation pubmed

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2017 · PMID 27908594 · validated civic_curation pubmed

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

· J Transl Med · 2016 · PMID 27154293 · validated civic_curation pubmed

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

· Br J Cancer · 2012 · PMID 23099803 · validated civic_curation pubmed

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

· N Engl J Med · 2012 · PMID 22187960 · validated civic_curation pubmed

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

· Gynecol Oncol · 2019 · PMID 30797591 · validated civic_curation pubmed

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.

· J Clin Oncol · 2025 · PMID 39413348 · validated civic_curation pubmed

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

· Br J Clin Pharmacol · 2015 · PMID 26033044 · validated civic_curation pubmed

Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.

· Oncotarget · 2015 · PMID 26311741 · validated civic_curation pubmed

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

· Bone Marrow Transplant · 2010 · PMID 19648970 · validated civic_curation pubmed

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

· Gynecol Oncol · 2010 · PMID 19840887 · validated civic_curation pubmed

TP53 polymorphism, HPV infection, and risk of cervical cancer.

· Cancer Epidemiol Biomarkers Prev · 2001 · PMID 11535556 · validated civic_curation pubmed

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

· Int J Gynaecol Obstet · 2008 · PMID 18555254 · validated civic_curation pubmed

A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.

· Oncol Lett · 2013 · PMID 24137399 · validated civic_curation pubmed